Tier 2 — strong

Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans

Sarah Egert, Siegfried Wolffram, Anja Bosy-Westphal, Christine Boesch-Saadatmandi, Anika Eva Wagner, Jan Frank, Gerald Rimbach, Manfred James Mueller
The Journal of nutrition 2008 138(9):1615

Bibliography

PubMed
PMID 18716159
DOI
10.1093/jn/138.9.1615
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized dose-ranging human supplementation study
ModelHuman intervention research
Sample35 healthy volunteers; pharmacokinetics measured in 15
InterventionQuercetin 50, 100, or 150 mg/day
Duration2 weeks
EndpointsLipid measurements; Inflammatory measures; Oxidative-stress measures; Exposure and pharmacokinetics

What the study showed, in plain terms

Published in 2008, this source examined forms, absorption and food sources. Design: Randomized dose-ranging human supplementation study. Sample/model: 35 healthy volunteers; pharmacokinetics measured in 15. The exposure or intervention was Quercetin 50, 100, or 150 mg/day. Follow-up or treatment period: 2 weeks.

Plasma quercetin increased with dose, but measured antioxidant, inflammatory, lipid, body-composition, and metabolic outcomes did not improve.

Short dose-ranging study without a zero-dose placebo arm described in the abstract; substantial individual variation limits prediction of exposure.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Plasma quercetin increased with dose, but measured antioxidant, inflammatory, lipid, body-composition, and metabolic outcomes did not improve.
  • The recorded outcome domains were Lipid measurements; Inflammatory measures; Oxidative-stress measures; Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin 50, 100, or 150 mg/day; 2 weeks.

What this study can and cannot tell us

  • Short dose-ranging study without a zero-dose placebo arm described in the abstract; substantial individual variation limits prediction of exposure.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology